Observational analysis of treatment with palbociclib in patients with rh+/her2- locally advanced and/or metastatic breast cancer in first-line treatment within routine clinical practice. PALBOCICLIB 2. PALBOSPAIN
INDEPENDENT POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: FOUNDATION FOR BIOMEDICAL RESEARCH OF THE SAN CARLOS CLINICAL HOSPITAL
- Execution start: 27/09/2021
- End of execution: 30/06/2023
- IP: ENCARNA GONZALEZ FLORES